Texts: "Exploring investor views on accounting for R&D costs under IAS 38." Read the above article and answer the following question: Are you in favor of the "expenses all" approach currently adopted by the US GAAP? Why or why not? (Less than 200 words)
The "expenses all" approach, which is currently adopted by the US GAAP (Generally Accepted Accounting Principles), refers to the practice of expensing all research and development (R&D) costs as incurred.
Personally, I am not in favor of the "expenses all" approach. While it may provide a more accurate representation of the financial position of a company in the short term, it fails to recognize the long-term value and potential benefits of R&D investments.
R&D activities are crucial for innovation and the development of new products and technologies. By expensing all R&D costs, companies may be discouraged from investing in these activities, as they would immediately impact their financial statements. This approach could hinder the progress and growth of industries that heavily rely on R&D, such as pharmaceuticals, technology, and biotechnology.
Alternatively, a capitalization approach, where R&D costs are capitalized and amortized over their useful life, could better reflect the economic value of these investments. This approach acknowledges that R&D expenditures can generate future benefits and should be recognized as assets. It allows for a more accurate assessment of a company's long-term prospects and potential for future growth.
In conclusion, while the "expenses all" approach may provide short-term clarity, it fails to capture the true value of R&D investments. A capitalization approach would better align with the importance of R&D activities and their potential impact on a company's future success.